Study Shows Pycnogenol® Reduces Risk of Post-Thrombotic Syndrome and Recurrent Thrombosis

The CDC estimates that 33 percent of those with DVT will have a recurrence within 10 years; new research shows French maritime pine bark extract can reduce this risk

News provided by

Pycnogenol

Oct 03, 2018, 16:13 ET

HOBOKEN, N.J., Oct. 3, 2018 /PRNewswire/ -- A new peer-reviewed study shows that daily supplementation with the natural super-antioxidant Pycnogenol® (pic-noj-en-all) may reduce the incidence of post-thrombotic syndrome (PTS) and recurrent thrombosis.

Post-thrombotic syndrome (PTS) is a long-term condition that occurs as a result of a deep vein thrombosis (DVT) and may affect mobility, and the symptoms include redness, swelling, ulcers, and chronic leg pain¹.

A new peer-reviewed study shows that daily supplementation with the natural super-antioxidant Pycnogenol® (pic-noj-en-all) may reduce the incidence of post-thrombotic syndrome (PTS) and recurrent thrombosis.

Study participants who supplemented with Pycnogenol® reported the lowest occurrence of thrombotic events compared to other test groups.

Recurrent thrombosis is a potentially life-threatening condition caused by another blood clot forming again in the lower leg. The CDC estimates that up to 100,000² Americans die of DVT-related complications each year, and up to 30 percent of those fatalities occur within one month of diagnosis.

"PTS and recurrent thrombosis can occur as a result of suffering from a DVT event. About 33 percent¹ of those who have DVT will have a recurrence within 10 years, and up to half of those individuals can have long-term complications from PTS," said Medical Director at NYU Langone, Dr. Steven Lamm. "This research is critical for individuals with high risk of thrombotic events. Driving or flying for long periods of time, heart failure, obesity and family history³ can all increase your risk of DVT. This study shows promising results for Pycnogenol® to reduce the risk of recurrent thrombosis and PTS."

The expansive study, published in Minerva Cardioangiologica, tested 815 individuals at-risk of post-thrombosis or recurrent thrombosis for six years following a thrombotic event. Five groups were tested in the study including a control group, aspirin group, ticlopidine group, sulodexide group and a Pycnogenol® group, to determine the efficacy of these treatment options for reducing occurrence of PTS and recurrent thrombosis.

All study participants followed a standard management routine including the use of antithrombotic stockings, a weight control regimen and regular exercise. Study participants were evaluated every six months for the duration of six years following their thrombotic event, and reports showed that participants who supplemented with Pycnogenol® experienced:

Significantly lowered incidence of recurrent thrombosis compared to other test groups (5.8 percent incidence in Pycnogenol® group vs. 17.2 percent in control group)
Greatly reduced occurrence of PTS (6.5 percent in Pycnogenol® group vs. 19.8 percent in control group)
Overall, the lowest occurrence of thrombotic events compared to other test groups

"Standard medical instruction for patients who have experienced a thrombotic event often includes taking aspirin, but that is not an option for millions. This research shows that Pycnogenol® can significantly reduce the risk of PTS and re-thrombosis more effectively than aspirin, which is particularly good for people who suffer from aspirin intolerance," said Dr. Lamm.

This new research builds upon recent studies showing the benefits of Pycnogenol® for circulatory health. A study conducted earlier in 2018 showed that supplementation with Pycnogenol® is effective in reducing lower leg swelling, known as edema, and relieving jet lag on long-haul flights and road trips. Edema is a major risk factor for DVT and can result from lack of activity or being confined in a small space for long periods of time.

Pycnogenol® is a powerful natural super-antioxidant shown in decades of research to promote healthy blood circulation and act as a natural anti-inflammatory. To review clinical research and additional information on Pycnogenol®, visit www.Pycnogenol.com. Pycnogenol® is available in more than 1,000 dietary supplements and multi-vitamins worldwide.

About Pycnogenol®

Pycnogenol^® is a natural plant extract originating from the bark of the maritime pine that grows along the coast of southwest France and is found to contain a unique combination of procyanidins, bioflavonoids and phenolic acids, which offer extensive natural health benefits. The extract has been widely studied for the past 40 years and has more than 420 published studies and review articles ensuring safety and efficacy as an ingredient. Today, Pycnogenol^® is available in more than 1,000 dietary supplements, multi-vitamins and health products worldwide. For more information, visit www.pycnogenol.com.

About Horphag Research (USA) Inc.

Horphag Research (USA) Inc., based in Hoboken, New Jersey, is the North American distributor for Pycnogenol^® (pic-noj-en-all) brand French maritime pine bark extract and Robuvit®, French oak wood extract on behalf of Horphag Research. Pycnogenol^® and Robuvit® are registered trademarks of Horphag Research Ltd. For its patented ingredient, Pycnogenol^®, Horphag Research has been awarded the Frost & Sullivan Excellence in Research Award, Nutraceutical Business & Technology Safety & Quality Award, SupplySide West Scientific Excellence Award and The American Botanical Council's Tyler Research Award. Horphag Research (USA) has the exclusive rights to market and sell Pycnogenol^® in North America and benefits from more than 40 years of scientific research assuring the safety and efficacy of Pycnogenol^® as a dietary supplement. For more information, visit www.pycnogenol.com and www.robuvit.com.